Intercytex and UHSM announce two initial projects for their partnership in Cell Therapy and Regenerative Medicine

Intercytex and UHSM announce two initial projects for their partnership in Cell Therapy and Regenerative Medicine


Intercytex Ltd and University Hospital South Manchester NHS Foundation Trust (‘UHSM’) today announced that their partnership in Cell Therapy and Regenerative Medicine is undertaking the development of a progressive clinical trials system and an advanced therapy manufacturing facility located within the Manchester Airport City Enterprise Zone.

The partnership intends to design a commercial GMP facility containing clean room suites with adjacent GMP laboratories and controlled environments that meets both EU and US GMP requirements. Once built, the facility would be operated by Intercytex as a Contract Manufacturing Facility and be part of the suite of Cell2Therapy services offered by Intercytex.  Critically, the chosen location is in close proximity to UHSM’s clinical trial unit, Manchester International Airport, the proposed airport HS2 station and the national motorway system. The intent is that material made in the facility could either be used quickly within the hospital or transported nationally or globally via these excellent communication links. Funding will be sought from private investors and from the public sector where appropriate benefits can be demonstrated. The facility will be a unique asset for the UK based in the North West that fits well with the government's Strategy for Life Sciences as well as the recent House of Lords' inquiry into Regenerative Medicine. Given the growing interest in regenerative medicine technologies from countries such as China it will also help attract inward investment into the Enterprise Zone.

Paul Kemp of Intercytex said: “We have designed and built cell therapy and regenerative medicine laboratories and GMP facilities in the past and the aim is to be able to build a manufacturing facility that is adaptable and able to expand as needed. Intercytex Ltd are the only UK commercial contract manufacturer specialising in Cell Therapy and Regenerative Medicine products and the only UK regenerative medicine company which has been directly involved in the manufacture of a cell therapy product used in a multi-centre, multi-national Phase III clinical trial. Our staff have an unparalleled amount of commercial experience in this sector.”

Simon Ray of UHSM said: “The location of a commercial GMP facility in the Enterprise Zone would be ideal. UHSM is a major teaching hospital that is a key part of MAHSC and the Greater Manchester healthcare and life science network. Our excellent road and rail links and the immediate proximity of an international airport and the proposed airport HS2 station make this advanced manufacturing facility a resource that can be utilised nationally and internationally and will help position the UK at the forefront of regenerative medicine and cell therapy. It is also another example of how we are innovating and collaborating with the private sector to find ways of delivering better healthcare outcomes.”

For more information contact Paul Kemp at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 0161 606 7204

Notes to Editors

**Intercytex (www.intercytex.com) is a UK biotech company based in Manchester dedicated to the development of Regenerative Medicine products and services.  It manufactures cell based products from its IMP licensed GMP manufacturing facility and has designed and run numerous cell therapy clinical studies in the UK, US and Europe both for itself and for third parties. Its lead product Vavelta / ICX-RHY is currently being investigated for the treatment of Epidermolysis Bullosa and Scar Contractures.

*UHSM (www.uhsm.nhs.uk) is a major acute teaching hospital trust providing services for adults and children at Wythenshawe Hospital and Withington Community Hospital, and community services. Fields of specialist expertise - include cardiology and cardiothoracic surgery, heart and lung transplantation, respiratory conditions, burns and plastics, cancer and breast care services. We are also recognised in the region and nationally for the quality of our teaching, research and development. Our major research programmes focus on cancer, lung disease, wound management and medical education.

E-mail Print PDF